v3.26.3
Segment Information (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Segment Reporting Information [Line Items]                  
Net operating losses $ 7,532     $ 6,725     $ 21,353 $ 20,746  
Segment net loss 7,250 $ 6,370 $ 6,780 6,530 $ 7,144 $ 6,302 20,400 19,976  
Total Assets 35,310           35,310   $ 39,393
Biopharm Division [Member]                  
Segment Reporting Information [Line Items]                  
Net operating losses 6,400           18,600    
Segment net loss 6,391     5,852     18,601 17,863  
Total Assets 34,700           34,700    
Neurostimulation Division [Member]                  
Segment Reporting Information [Line Items]                  
Net operating losses 900           1,800    
Segment net loss 859     $ 678     1,799 $ 2,113  
Total Assets $ 600           $ 600